Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/taylor-francis/antisense-approach-for-the-treatment-of-cytomegalovirus-infection-LN1EBvW0aL
References (45)
-
K Anderson, M. Fox, V. Brown-Driver, M Martin, R. Azad (1996)
Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNAAntimicrobial Agents and Chemotherapy, 40
-
V. Metelev, J. Lisziewicz, S. Agrawal (1994)
Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotidesBioorganic & Medicinal Chemistry Letters, 4
-
Z. Zhang, Jansen Smith, AP Smyth, J.‐Y. Tang, W. Eisenberg, GS Pari (1997)
Inhibition of Human Cytomegalovirus DNA Replication with a Phosphorothioate Cholesteryl-Modified Oligonucleotide is Mediated by Rapid Cellular Association and Virus-Facilitated Nuclear LocalizationAntiviral Chemistry and Chemotherapy, 8
-
J. Smith, G. Pari (1995)
Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replicationJournal of Virology, 69
-
S. Paul, S. Dummer (1992)
Topics in clinical pharmacology: ganciclovir.The American journal of the medical sciences, 304 4
-
(1977)
TOLKOFF-RUBIN NE, RUSSELL PS, HIRSCH MS: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients, 24
-
G. Pari, M Kacica, D. Anders (1993)
Open reading frames UL44, IRS1/TRS1, and UL36-38 are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA synthesisJournal of Virology, 67
-
D. Jabs, C. Enger, J. Bartlett (1989)
Cytomegalovirus retinitis and acquired immunodeficiency syndrome.Archives of ophthalmology, 107 1
-
(1986)
Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in pa-tients with AIDS and other immunodeficiencies, 27
-
S. Spector, G. Mckinley, J. Lalezari, T. Samo, R. Andruczk, S. Follansbee, P. Sparti, D. Havlir, G. Simpson, William Buhles, R. Wong, M. Stempien (1996)
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.The New England journal of medicine, 334 23
-
P. McAuliffe, M. Hall, H. Castro-Malaspina, M. Heinemann (1997)
Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation.American journal of ophthalmology, 123 5
-
(1997)
Pharmacologic management of cytomega-@ lovirus retinitis: review of current and future therapeu-tic modalities, 68
-
A. Field, J. Goodchild (1995)
Antisense oligonucleotides: Rational drug design for genetic pharmacology -
A. Padmapriya, J. Tang, S. Agrawal (1994)
Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates.Antisense research and development, 4 3
-
M. Stephenson, P. Zamecnik (1978)
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.Proceedings of the National Academy of Sciences of the United States of America, 75 1
-
Gregory PARItAND, D. Anders (1993)
Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replicationJournal of Virology, 67
-
David Ecker, Timothy Vickers, TW Bruice, Susan Freier, RD Jenison, Muthiah Manoharan, M. Zounes (1992)
Pseudo--half-knot formation with RNA.Science, 257 5072
-
Paul Chrisp, S. Clissold (2012)
FoscarnetDrugs, 41
-
Frans Stals, E. Clercq, Cathrien BRUGGEMANt (1991)
Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivoAntimicrobial Agents and Chemotherapy, 35
-
J. Temsamani, S. Agrawal, T. Pederson (1991)
Biotinylated antisense methylphosphonate oligodeoxynucleotides. Inhibition of spliceosome assembly and affinity selection of U1 and U2 small nuclear RNPs.The Journal of biological chemistry, 266 1
-
S. Agrawal, J. Temsamani, W. Galbraith, J. Tang (1995)
Pharmacokinetics of Antisense OligonucleotidesClinical Pharmacokinetics, 28
-
S. Agrawal (1992)
Antisense oligonucleotides as antiviral agents.Trends in biotechnology, 10 5
-
Gregory Pari, A. Field, Jean Smith (1995)
Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37Antimicrobial Agents and Chemotherapy, 39
-
D. Henderly, W. Freeman, D. Causey, N. Rao (1987)
Cytomegalovirus retinitis and response to therapy with ganciclovir.Ophthalmology, 94 4
-
G. Zon, T. Geiser (1991)
Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions.Anti-cancer drug design, 6 6
-
S. Marker, R. Howard, R. Simmons, J. Kalis, D. Connelly, J. Najarian, H. Balfour (1981)
Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants.Surgery, 89 6
-
Q. Zhao, S. Matson, C. Herrera, E. Fisher, H. Yu, A. Krieg (1993)
Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.Antisense research and development, 3 1
-
S. Crooke (1996)
Monthly Updates: Monthly Update Biologicals & Immunologicals: Progress in the development of antisense drugsExpert Opinion on Investigational Drugs, 5
-
R. Rubin, A. Cosimi, N. Tolkoff-Rubin, P. Russell, M. Hirsch (1977)
INFECTIOUS DISEASE SYNDROMES ATTRIBUTABLE TO CYTOMEGALOVIRUS AND THEIR SIGNIFICANCE AMONG RENAL TRANSPLANT RECIPIENTSTransplantation, 24
-
(2010)
Cytomegaloviruses, 1990
-
E. Prisbe, J. Martin, D. McGee, M. Barker, D. Smee, A. Duke, T. Matthews, J. Verheyden (1986)
Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine.Journal of medicinal chemistry, 29 5
-
S. Agrawal, Z. Jiang, Q. Zhao, D. Shaw, Q. Cai, A. Roskey, L. Channavajjala, C. Saxinger, R. Zhang (1997)
Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.Proceedings of the National Academy of Sciences of the United States of America, 94 6
-
R. Azad, V. Driver, K. Tanaka, R. Crooke, K. Anderson (1993)
Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early regionAntimicrobial Agents and Chemotherapy, 37
-
L. Castro, E. Kern, E. Clercq, A. Ghaffar, E. Mayer, P. Vogt, J. Gangemi (1991)
Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.Antiviral research, 16 1
-
M. Challberg (1986)
A method for identifying the viral genes required for herpesvirus DNA replication.Proceedings of the National Academy of Sciences of the United States of America, 83 23
-
Saghir Akhtar, Rudy Juliano (1992)
Cellular uptake and intracellular fate of antisense oligonucleotides.Trends in cell biology, 2 5
-
D. Faulds, Rennte Heel (2012)
GanciclovirDrugs, 39
-
J. Temsamani, M. Kubert, J. Tang, A. Padmapriya, S. Agrawal (1994)
Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs.Antisense research and development, 4 1
-
P. Zamecnik, M. Stephenson (1978)
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences of the United States of America, 75 1
-
M. Levinson, P. Jacobson (1992)
Treatment and Prophylaxis of Cytomegalovirus DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 12
-
(1997)
CASTRO-MALASPINA H, HEINE-MANN MH: Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosup-pression after bone marrow transplantation, 123
-
S. Loke, C. Stein, X. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J. Cohen, L. Neckers (1989)
Characterization of oligonucleotide transport into living cells.Proceedings of the National Academy of Sciences of the United States of America, 86 10
-
(1981)
Cytomega-lovirus infection: a quantitative prospective study of 320 consecutive renal transplants, 89
-
(1988)
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS), 108
-
M. Jacobson, W. Drew, J. Feinberg, J. O'Donnell, P. Whitmore, R. Miner, D. Parenti (1991)
Foscarnet Therapy for Ganciclovir-Resistant Cytomegalovirus Retinitis in Patients with AIDSThe Journal of Infectious Diseases, 163
- Publisher
- Taylor & Francis
- Copyright
- © 1997 Ashley Publications Ltd.
- ISSN
- 1744-7658
- eISSN
- 1354-3784
- DOI
- 10.1517/13543784.6.9.1157
- Publisher site
- See Article on Publisher Site
Abstract
Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is the most frequent manifestation of HCMV infection, occurring in 15 - 40% of all patients. HCMV is progressive and destroys the retina, eventually leading to blindness. Although, there are several drugs available to treat this disease, they are often of limited efficacy and have significant side-effects. Antisense oligonucleotides represent a novel alternative to the currently available drugs. Due to their high affinity and specificity to target the HCMV RNAs, interest in antisense technology to treat HCMV infections has been intense during the past few years. Two antisense drugs are currently in clinical trials, ISIS 2922 (Formivirsen) and GEM®132.
Journal
Expert Opinion on Investigational Drugs – Taylor & Francis
Published: Sep 1, 1997
Keywords: antisense oligonucleotides; clinical trials; human cytomegalovirus